Zura Bio Ltd 8-K

What Happened
Zura Bio Ltd (filed as ZURA) filed a Form 8-K on January 12, 2026 furnishing an updated corporate presentation (Exhibit 99.1) and issuing a press release (Exhibit 99.2). The press release announces corporate and clinical trial updates and the company’s 2026 outlook, including information on its cash runway and expected topline data readout timelines for two ongoing Phase 2 studies of tibulizumab, Zura Bio’s lead dual‑pathway antibody, in hidradenitis suppurativa and systemic sclerosis. The presentation is also posted in the “News & Events” section of the company’s investor website.

Key Details

• Filing date: January 12, 2026 (Form 8-K; Exhibits 99.1 and 99.2 furnished).
• Corporate presentation (Exhibit 99.1) updated and available at investors.zurabio.com.
• Press release (Exhibit 99.2) provides corporate and clinical updates, including cash runway information and expected topline readout timelines for two Phase 2 tibulizumab trials (hidradenitis suppurativa and systemic sclerosis).
• Disclosure made under Regulation FD and as an “Other Event” in Item 8.01.

Why It Matters
This filing gives investors an updated view of Zura Bio’s clinical development schedule and near‑term corporate outlook—particularly when topline Phase 2 results for tibulizumab might be available and how long the company expects its funding to support operations. Such updates can affect investor expectations around clinical milestones and financing needs. The filing does not include financial results, executive changes, or definitive readout dates; investors should monitor subsequent announcements and company filings for precise timelines and financial details.